REFERENCES
- Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006; 20 (3): 507-44, v-vi.
- Diamond RD, Bennett JE. Prognostic factors in crypto-coccal meningitis. A study in 111 cases. Ann Intern Med 1974; 80 (2): 176-81.
- Perfect JR. Cryptococcus neoformans. In: Mandel GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Churchill Livingstone 2005: 2997–3012.
- Whimbey E, Gold JW, Polsky B, Dnjjanski J, Hawkins C, Blevins A, et al. Bacteremia and fungemia in patients with the ac-quired immunodeficiency syndrome. Ann Intern Med 1986; 104 (4): 511–4.
- Jean SS, Fang CT, Shau WY, Chen YC, Chang SC, Hsueh PR, et al. Cryptococcaemia: clinical features and prognostic factors. Qjm 2002; 95 (8): 511–8.
- Prendiville S, Bielamowicz SA, Hawrych A, Deeb ZE. Iso-lated cryptococcal sphenoid sinusitis with septicemia, meningi-tis, and subsequent skull base osteomyelitis in an immunocompetent patient. Otolanjngol Head Neck Surg 2000; 123 (3): 277–9.
- Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anti-cancer Ther 2005; 5 (1): 39-51.
- Thursky KA, Worth U, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for pro-phylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006; 132 (1): 3–12.
- Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43 (1): 16–24.
- Nosari A, Tedeschi A, Ricci F, Montillo M. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica 2008; 93 (2): e30–1.
- Molica S, Levato D, Levato L. Infections in chronic lym-phocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 1993; 78 (6): 374–7.
- Ravandi F, Anaissie EJ, O'Brien S. Infections in chronic leukemias and other haematological malignancies. In: Bowden JR, Wa RA, editor. Management of Infection in Oncology Patients. London: Martin Dunitz; 2003. p. 105-128.
- Tam CS, Wolf MM, Januszewicz EH, Grigg AP, Prince HM, Westerman D, et al. A new model for predicting infectious complications during fludarabine-based combination chemother-apy among patients with indolent lymphoid malignancies. Can-cer 2004; 101 (9): 2042–9.
- Laros-van Gorkom BA, Huisman CA, Wijermans PW, Schipperus MR. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Neth J Med 2007; 65 (9): 333–8.
- Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44 (2): 204–12.
- Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005; 37 (2): 934–6.
- Silveira FP, Husain S, Kwak EJ, Linden PK, Marcos A, Shapiro R, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis 2007; 9 (1): 22–7.
- Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infec-tious complications in adult renal transplantation. Transplanta-tion 2006; 81 (1): 17–20.
- Walsh R, Ortiz J, Foster P, Palma-Vargas J, Rosenblatt S, Wright F. Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation. Transpl Infect Dis 2008; 10 (4): 236–9.
- Ortiz J, Palma-Vargas J, Wright F, Bingaman A, Agha I, Rosenblatt S, et al. Campath induction for kidney transplanta-tion: report of 297 cases. Transplantation 2008; 85 (11): 1550–6.
- Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007; 78 (4): 275–82.